20th November 2020 – Glycostem today announced the opening of a phase I/IIa trial for its lead product oNKord® for the treatment of AML patients. The WiNK trial will enroll 33 AML patients at eight clinical sites based in five European countries. oNKord® is the company’s first-generation off-the-shelf allogeneic NK cellular immunotherapy product. Glycostem is furthermore developing a range of second (CAR-NK) and third generation (TCR-NK) NK products in-house.